| 7.87 0.15 (1.94%) | 04-24 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.51 | 1-year : | 11.11 |
| Resists | First : | 8.14 | Second : | 9.51 |
| Pivot price | 7.36 |
|||
| Supports | First : | 6.51 | Second : | 5.5 |
| MAs | MA(5) : | 7.67 |
MA(20) : | 7.42  |
| MA(100) : | 6 |
MA(250) : | 5.63 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 81.3 |
D(3) : | 74.7 |
| RSI | RSI(14): 63.8 |
|||
| 52-week | High : | 8.14 | Low : | 3.67 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CCEL ] has closed below upper band by 12.5%. Bollinger Bands are 3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.91 - 7.94 | 7.94 - 7.97 |
| Low: | 7.61 - 7.65 | 7.65 - 7.69 |
| Close: | 7.8 - 7.87 | 7.87 - 7.92 |
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Mon, 15 Apr 2024
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results - Business Wire
Mon, 15 Apr 2024
CCEL Stock Earnings: Cryo-Cell International Beats EPS, Misses Revenue for Q1 2024 - InvestorPlace
Thu, 28 Mar 2024
Short Interest in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Expands By 140.9% - MarketBeat
Tue, 26 Mar 2024
Cryo-Cell International Announces Strategic Subsidiary Spin-Off Plans - TipRanks.com - TipRanks
Mon, 25 Mar 2024
Cryo-Cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value - Business Wire
Wed, 28 Feb 2024
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023 - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 8 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 46.1 (%) |
| Held by Institutions | 10.1 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | 0.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0 |
| Profit Margin | 8 % |
| Operating Margin | 16.3 % |
| Return on Assets (ttm) | 4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 2.5 % |
| Gross Profit (p.s.) | 2.59 |
| Sales Per Share | 3.76 |
| EBITDA (p.s.) | 0.7 |
| Qtrly Earnings Growth | 43.7 % |
| Operating Cash Flow | 8 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | 26.23 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 2.08 |
| Price to Cash Flow | 8.14 |
| Dividend | 0.89 |
| Forward Dividend | 0 |
| Dividend Yield | 11.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|